<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757042</url>
  </required_header>
  <id_info>
    <org_study_id>20070620</org_study_id>
    <nct_id>NCT00757042</nct_id>
  </id_info>
  <brief_title>Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This study is a phase 1 single dose escalation study of AMG 157 in healthy subjects and
      subjects with moderate to severe atopic dermatitis. The purpose of the study is to evaluate
      the safety, tolerability and pharmacokinetics of AMG 157.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluations: Subject incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations, laboratory safety tests, ECGs, and the development of anti-AMG 157 antibodies</measure>
    <time_frame>Part A - 85 days; Part B - 113 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eczema Area &amp; Severity Index (EASI) score and Investigator's Global Assessment (IGA) score</measure>
    <time_frame>Part B only - 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PK parameters</measure>
    <time_frame>Part A - 85 days; Part B - 113 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AMG 157</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects in each cohort (cohort 1 to 8) will receive AMG 157 in Part A 18 subjects in cohorts 9 and 10 (Part B) will receive AMG 157</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 subjects of each cohort (cohort 1 to 8) will receive placebo in Part A 6 subjects in cohorts 9 and 10 (Part B) will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 157</intervention_name>
    <description>Part A (healthy subjects): 6 subcutaneous (SC) cohorts and 2 intravenous (IV) cohorts receiving a single dose of either AMG 157 (dose escalating by cohort) or placebo. Part B (subjects with moderate to severe atopic dermatitis):two cohorts receiving a single dose (SC or IV; dose to be determined) of AMG 157 or placebo.</description>
    <arm_group_label>AMG 157</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must sign an Institutional Review Board (IRB) approved informed consent form
             before any study specific procedures

          -  Subjects must be aged between 18 and 45 years, inclusive (Part A only)

          -  Female subjects must be of non-reproductive potential

          -  Male subjects with partners of childbearing potential should inform their partner of
             their participation in this clinical study and use highly effective methods of birth
             control during the study

          -  Healthy subjects must have a body mass index (BMI) between 18 to 32 kg/m2, inclusive

          -  Subject must have normal or clinically acceptable physical examination, clinical
             laboratory tests and electrocardiogram (ECG) results

          -  For Part B, Subject must have active AD affecting ≥10% body surface area; EASI score
             ≥15, aged between 18 and 60 years, inclusive and BMI between 18 and 35 kg/m2,
             inclusive

        Exclusion Criteria:

          -  Subject who has history or evidence of a clinically significant disorder, condition or
             disease that, in the opinion of the Investigator in consultation with the Amgen
             physician, would pose a risk to subject safety or interfere with the study evaluation,
             procedures or completion

          -  Subject who has evidence of any active or suspected bacterial, viral, fungal or
             parasitic infections within the past 30 days prior to randomization

          -  Subject who has known positive tuberculin skin test or recent (within 6 months from
             randomization) exposure to an individual with active tuberculosis

          -  Subject who has history of malignancy within 5 years before randomization

          -  Subject who has history of significant dermatological conditions (except for atopic
             dermatitis in Part B)

          -  Subject who has previously received any investigational drug (or is currently using an
             investigational device) within 30 days prior to randomization

          -  Subject who has tested positive for drugs and/or alcohol use at screening or before
             randomization

          -  Female subjects who are pregnant or lactating

          -  Subject who has used nicotine or tobacco containing products during 6 months before
             randomization and during the study (except for Part B below)

          -  For atopic dermatitis subjects in Part B (Cohorts 9 and 10) only, additional exclusion
             criteria are as follows:

        Subject who has concurrent skin disease (eg, acne) of such severity in the study area that
        it could interfere with study evaluation; Subject who has active or recent skin infections
        (within 7 days of randomization); Subject who has received phototherapy (eg, UVA, UVB)
        known or suspected to have an effect on AD within 6 weeks prior to randomization; Subject
        who has received corticosteroids by other than topical, inhaled or intranasal delivery
        within 4 weeks prior to randomization; Subject who has been treated with topical
        calcineurin inhibitors within 14 days prior to randomization; Subject who uses any
        medications that interfere with blood coagulation (eg NSAIDs) or wound healing within 7
        days or 5 half-lives (whichever is longer) prior to enrolling into the study and for the
        duration of the study.

        Subject who smokes more than 10 cigarettes per day within the 6 months prior to
        randomization and during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>skin diseases</keyword>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

